Abstract
Metabolic syndrome (MS) is a modern medical condition characterized by central obesity, hyperglycaemia, hypercholesterolemia and hypertension. The beneficial effects of mushrooms in lowering the symptoms of MS were known from both traditional and conventional medicine. Edible mushrooms, their extracts, polysaccharide fractions and isolated compounds possessed hypoglycaemic, cholesterol and triglyceride lowering ability, hypotensive effects, as well as weight managing activity by influencing satiety. The most active compounds are polysaccharides, called β-glucans, as well as lectines and small compounds such as eritadenin, triterpenes, sterols and phenolic compounds.
Keywords: Antihypertensive, hypoglycaemic, hypolipidemic, mushrooms, metabolic syndrome, weight loss.
Current Topics in Medicinal Chemistry
Title:Therapeutic Properties of Mushrooms in Managing Adverse Effects in the Metabolic Syndrome
Volume: 13 Issue: 21
Author(s): Tatjana Kundakovic and Marina Kolundzic
Affiliation:
Keywords: Antihypertensive, hypoglycaemic, hypolipidemic, mushrooms, metabolic syndrome, weight loss.
Abstract: Metabolic syndrome (MS) is a modern medical condition characterized by central obesity, hyperglycaemia, hypercholesterolemia and hypertension. The beneficial effects of mushrooms in lowering the symptoms of MS were known from both traditional and conventional medicine. Edible mushrooms, their extracts, polysaccharide fractions and isolated compounds possessed hypoglycaemic, cholesterol and triglyceride lowering ability, hypotensive effects, as well as weight managing activity by influencing satiety. The most active compounds are polysaccharides, called β-glucans, as well as lectines and small compounds such as eritadenin, triterpenes, sterols and phenolic compounds.
Export Options
About this article
Cite this article as:
Kundakovic Tatjana and Kolundzic Marina, Therapeutic Properties of Mushrooms in Managing Adverse Effects in the Metabolic Syndrome, Current Topics in Medicinal Chemistry 2013; 13 (21) . https://dx.doi.org/10.2174/15680266113136660196
DOI https://dx.doi.org/10.2174/15680266113136660196 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools
Protein & Peptide Letters The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure
Current Pharmaceutical Design Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population
Current Psychopharmacology Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology Statins in Bacteremia, Sepsis and Pneumonia: Have We Found the Holy Grail?
Recent Patents on Inflammation & Allergy Drug Discovery Induction of Cytochrome P450 3A by the Ginkgo biloba Extract and Bilobalides in Human and Rat Primary Hepatocytes
Drug Metabolism Letters Autonomic Dysfunction and Depression: A Biomarker of MDD Across the Life Span
Current Psychiatry Reviews The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Interaction Between KATP-Channels and Protein Kinase C in the Regulation of Basal Coronary Flow
Vascular Disease Prevention (Discontinued) Toward a Discipline of Pharmacoepigenomics
Current Pharmacogenomics Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics Opioids and Cannabinoids Interactions: Involvement in Pain Management
Current Drug Targets Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Effects of <I>Gentiana lutea</I> Root on Vascular Diseases
Current Vascular Pharmacology